Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus

Prostaglandins and Other Lipid Mediators

Volumn 57, Issue 2-3, 1999, Pages 87-98

  Kudolo, George B ^a   Defronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Albuminuria; Non insulin dependent diabetes mellitus; Platelet activating factor

Indexed keywords

GLUCOSE; INSULIN; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROTEINURIA; URINALYSIS; URINE LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; KIDNEY FUNCTION TESTS; MEXICAN AMERICANS; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PROTEINURIA;

EID: 0033056733     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(98)00074-4     Document Type: Article

References (45)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
2. DeFronzo R.A., Ferrannini E. Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease . Diabetes Care. 14:1991;173-194.
3. Haffner S.M., Valdez R.A., Hazuda H.P., Mitchell B.D., Morales P.A., Stern M.P. Prospective analysis of the insulin resistance syndrome (Syndrome X). Diabetes. 41:1992;715-722.
4. Mogensen C.E. Natural history of renal functional abnormalities in human diabetes mellitus from normoalbuminuria to incipient and overt nephropathy . Brenner B.M., Stein J.H. The Kidney in Diabetes Mellitus. 1989;19-49 Churchill Livingstone, New York.
5. Groop L., Ekstrand A., Forsblom C., Widen E., Groop P.-H., Teppo A.M., Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin dependent diabetes). Diabetes/Metab Rev. 4:1988;727-727.
6. Bianchi S., Bigazzi R., Galvan A.Q., Muscelli E., et al. Insulin resistance in microalbuminuric hypertension. Sites and Mechanisms. Hypertension. 26:1995;789-795.
7. Sowers J.R., Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. An update. Hypertension. 26:1995;869-879.
8. Kudolo G.B., Bressler P., DeFronzo R.A. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity effect of hyperinsulinemia and lovastatin treatment . J Lipid Mediat Cell Signal. 17:1997;97-112.
9. Lai F.M., Shepherd C.A., Cervoni P., Wissner A. Hypotensive and vasodilatory activity of 1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine in the normotensive rat. Life Sci. 32:1983;1159-1166.
10. Braquet P., Shen T.Y., Touqui L., Vargraftig B.B. Perspectives in platelet-activating factor research. Pharmacol Rev. 39:1987;97-145.
11. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol. 259:1990;C697-C708.
12. Camussi G., Aglietta M., Coda R., Bussolino F., Piacibello W., Teta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF monocytes, polymorphonuclear neutrophils and basophils . Immunology. 42:1981;191-195.
13. Prescott S.M., Zimmerman G.A., McIntire T.M. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA. 81:1984;3534-3538.
14. Pirotzky E., Bidault J., Burtin T., Gubler M.C., Benveniste J. Release of platelet-activating factor, slow-reacting substance and vasoactive amines from isolated rat kidneys. Kidney Int. 25:1984;404-410.
15. Pirotzky E., Braquet P. PAF-acether and kidney pathology. Prog Biochem Pharmacol. 22:1988;168-180.
16. Kudolo G.B., Harper M.J.K. Lyso-PAF:acetyl-CoA acetyltransferase and CDP-choline cholinephosphotransferase activities in the rabbit endometrium. J Lipid Mediat Cell Signal. 11:1995;145-158.
17. Kudolo G.B., Koopmans S.-J., Haywood J.R., DeFronzo R.A. Chronic hyperinsulinemia inhibits platelet-activating factor (PAF) biosynthesis in the rat kidney. J Lipid Mediat Cell Signal. 16:1997;23-37.
18. Hebert R.L., Sirois P., Braquet P., Plante G.E. Hemodynamic effects of PAF-acether on the dog kidney. Prostag Leukot Med. 26:1987;189-202.
19. Perico N., Delaini F., Tagliaferri M., Abbate M., Cucchi M., Bertani T., Remuzzi G. Effect of platelet-activating factor and its receptor antagonist on glomerular permeability in proteins in isolated perfused rat kidney. Lab Invest. 58:1988;163-171.
20. Morigi M., Macconi D., Riccardi E., Bocardo P., Zilio P., Bertani T., Remuzzi G. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. J Pharmacol Exp Ther. 258:1991;601-606.
21. Denjean A., Arnoux B., Masse R., Lockhart A., Benveniste J. Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol. 55:1983;779-804.
22. Rabinovici R., Yue T.-L., Geuerstein G. Platelet-activating factor in cardiovascular stress situations. Lipids. 26:1991;1257-1263.
23. Blank M.L., Lee T., Fitzgerald V., Snyder F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem. 256:1981;175-178.
24. Yanoshita, Kudo I., Ikizawa K., Chang H.W., Kobayashi S., Ohno M., et al. Hydrolysis of platelet-activating factor and its methylated analogs by acetylhydrolases. J Biochem. 103:1988;815-819.
25. Satoh K., Imaizumi T-a, Kawamura Y., Yoshida H., Takamatsu S., Takamatsu M. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins. 37:1989;673-682.
26. Eggers P.W. Mortality rates among dialysis patients in Medicare's end-stage renal disease program. Am J Kidney Dis. 15:1990;414-421.
27. Classification and diagnosis of diabetes and other categories of glucose tolerance. Diabetes. 28:1979;1039-1057.
28. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique a method for quantifying insulin secretion and resistance . Am J Physiol. 237:1979;E214-E223.
29. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:1959;911-917.
30. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
31. Ortiz A., Gomez-Charri M., Larma J.L., Gonzalez E., Egido J. The role of platelet-activating factor in experimental glomerular injury. Lipid. 26:1991;1310-1315.
32. Noris M., Benigni A., Boccardo P., Gotti E., Benfaniti E., Aiello S., Todeschini M., Remuzzi G. Urinary excretion of platelet-activating factor in patients with immune-mediated glomerulonephritis. Kidney Int. 43:1993;426-429.
33. Woodard D.S., Lee T-c, Snyder F. The final step in the de novo biosynthesis of platelet-activating factor. Properties of a unique CDP-choline:1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase in microsomes from the renal inner medulla of rats. J Biol Chem. 262:1987;2520-2527.
34. Lee T-c, Malone B., Snyder F. Formation of 1-alkyl-2- acetyl-sn-glycerols via the de novo biosynthetic pathway for platelet-activating factor. Characterization of 1-alkyl-2- acetyl-sn-glycero-3-phosphate phosphorylase in rat spleens. J Biol Chem. 263:1988;1755-1760.
35. Uemura T., Lee T.-C., Snyder F. A coenzyme A-independent transacylase is linked to the formation of platelet- activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J Biol Chem. 266:1991;8266-8272.
36. Sanchez-Crespo M., Inarrea P., Alvarez V., Alonso F., Egido J., Hernando L. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. Am J Physiol. 244:1983;F706-F711.
37. Ikeda I., Oda M., Sakakura M., Yasunaga K. Presence of platelet-activating factor in pyuria in humans. Lipids. 12:1991;1333-1335.
38. Bustos C., Gonzalez E., Gonzalez Cuadrado S., Ortiz A., et al. Urinary excretion of platelet-activating factor in human and experimental nephrosis. Nephrol Dial Transplant. 11:1996;282-286.
39. Srivastava S., Joshi C.S., Sethi P.P., Agrawal A.K., Srivasta S.K., Seth P.K. Altered platelet functions in non-insulin dependent diabetes mellitus. Throm Res. 76:1994;451-461.
40. Trovati M., Mularoni E.M., Burzacca S., Ponziani M.C., et al. Impaired insulin-induced platelet anti-aggregating effect in obesity and in obese NIDDM patients. Diabetes. 44:1995;1318-1322.
41. Oskarsson H.J., Hofmeyer T.G. Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation. J Am Coll Cardiol. 27:1996;6-12.
42. McManus L., Hanahan D.J., Demopoulos C.A., Pinckard R.N. Pathobiology of the i.v. infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol. 124:1980;2919-2924.
43. Ostermann G., Rühling K., Zabel-Langhennig, Winkler L., Schlag B., Till U. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Throm Res. 47:1987;279-285.
44. Graham R.M., Stephens C.J., Sturm M.J., Taylor R.R. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin Sc. 82:1992;535-541.
45. Lam K.S., Cheng I.K., Janus E.D., Pang R.W. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 38:1995;604-609.